CA2453173C - Mycobacterial antigens expressed during latency - Google Patents

Mycobacterial antigens expressed during latency Download PDF

Info

Publication number
CA2453173C
CA2453173C CA2453173A CA2453173A CA2453173C CA 2453173 C CA2453173 C CA 2453173C CA 2453173 A CA2453173 A CA 2453173A CA 2453173 A CA2453173 A CA 2453173A CA 2453173 C CA2453173 C CA 2453173C
Authority
CA
Canada
Prior art keywords
ala
leu
val
gly
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2453173A
Other languages
English (en)
French (fr)
Other versions
CA2453173A1 (en
Inventor
Brian William James
Philip Marsh
Tobias Hampshire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Department of Health and Social Care
Original Assignee
Department of Health and Social Care
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0116385A external-priority patent/GB0116385D0/en
Priority claimed from GB0123993A external-priority patent/GB0123993D0/en
Application filed by Department of Health and Social Care filed Critical Department of Health and Social Care
Publication of CA2453173A1 publication Critical patent/CA2453173A1/en
Application granted granted Critical
Publication of CA2453173C publication Critical patent/CA2453173C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2453173A 2001-07-04 2002-07-04 Mycobacterial antigens expressed during latency Expired - Fee Related CA2453173C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0116385A GB0116385D0 (en) 2001-07-04 2001-07-04 Mycobacterial antigens expressed during latency
GB0116385.6 2001-07-04
GB0123993.8 2001-10-05
GB0123993A GB0123993D0 (en) 2001-10-05 2001-10-05 Mycobacterial antigens expressed during latency
PCT/GB2002/003052 WO2003004520A2 (en) 2001-07-04 2002-07-04 Mycobacterial antigens expressed during latency

Publications (2)

Publication Number Publication Date
CA2453173A1 CA2453173A1 (en) 2003-01-16
CA2453173C true CA2453173C (en) 2013-12-10

Family

ID=26246282

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2453173A Expired - Fee Related CA2453173C (en) 2001-07-04 2002-07-04 Mycobacterial antigens expressed during latency

Country Status (6)

Country Link
US (3) US7393540B2 (enExample)
EP (2) EP1404706A2 (enExample)
JP (1) JP2005508613A (enExample)
AU (2) AU2002314358C1 (enExample)
CA (1) CA2453173C (enExample)
WO (1) WO2003004520A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806093D0 (en) * 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
AU2002317940B9 (en) 2001-06-22 2008-06-05 The Secretary Of State For Health Mycobacterial antigens expressed under low oxygen tension
US7393540B2 (en) 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
GB0125535D0 (en) * 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
WO2004067718A2 (en) * 2003-01-24 2004-08-12 Emory University Necrosis-deficient mutants of tuberculosis bacteria
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
EA013016B1 (ru) * 2005-03-31 2010-02-26 Лейден Юниверсити Медикал Сентер Способы и средства диагностики, профилактики и лечения инфекций mycobacterium и заболевания туберкулезом
WO2006117538A2 (en) * 2005-04-29 2006-11-09 Fusion Antibodies Limited Assays for diagnosis of tuberculosis and uses thereof
US7968105B2 (en) 2005-06-23 2011-06-28 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
EP2305701A1 (en) 2005-07-01 2011-04-06 Forsyth Dental Infirmary for Children Tuberculosis antigen detection assays and vaccines
ATE466876T1 (de) * 2005-08-09 2010-05-15 Hav Vaccines Ltd Immunogene konstrukte
US7601357B2 (en) * 2005-12-07 2009-10-13 University Of Central Florida Research Foundation, Inc. Targeting of long chain triacylglycerol hydrolase gene for tuberculosis treatment
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
EP1996732A4 (en) * 2006-03-02 2010-03-31 Uab Research Foundation RECOGNITION AND TREATMENT AND DISCOVERY OF REMEDIES AGAINST MYCOBACTERIAL DISEASES
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
US20110129817A1 (en) * 2009-11-30 2011-06-02 Baylor Research Institute Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection
KR20110036590A (ko) * 2008-06-25 2011-04-07 베일러 리서치 인스티튜트 결핵균 감염의 혈액 전사 시그너처
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
ES2335177B1 (es) 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
US8961989B2 (en) 2009-11-20 2015-02-24 Oregon Health & Science University Methods for producing an immune response to tuberculosis
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
ITRM20100411A1 (it) * 2010-07-23 2012-01-24 Massimo Amicosante Uso di sequenze amminoacidiche da mycobacterium tuberculosis o dei loro corrispondenti acidi nucleici per la diagnosi e la prevenzione di infezione tubercolare, relativo kit diagnostico e vaccino.
BR112013017267B1 (pt) 2011-01-04 2021-06-22 Archivel Farma, Sl Formulação de lipossomas, suspensão e composição farmacêutica
EP2471511A1 (en) 2011-01-04 2012-07-04 Archivel Farma, SL Liposome formulation suitable for treating or preventing tuberculosis
WO2012138754A2 (en) * 2011-04-04 2012-10-11 Beth Israel Deaconess Medical Center, Inc. Mycobacterial vaccine vectors and methods of using the same
AU2012301873A1 (en) 2011-08-30 2014-03-20 The Uab Research Foundation Mycobacterium tuberculosis porins and toxins and related methods
US10703784B2 (en) * 2011-09-30 2020-07-07 La Jolla Institute For Allergy And Immunology Antigens and epitopes derived from Mycobacterium tuberculosis
US20140349320A1 (en) * 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
SG11201500171YA (en) 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
US10197560B2 (en) 2013-06-27 2019-02-05 The Brigham And Women's Hospital, Inc. Methods and systems for determining M. tuberculosis infection
EP3092000A1 (en) 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
GB201400819D0 (en) 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition
WO2016024129A1 (en) * 2014-08-15 2016-02-18 Oxford Immunotec Limited Mycobacterium tuberculosis proteins
CN108267588B (zh) * 2016-12-30 2020-10-23 首都医科大学附属北京胸科医院 结核分枝杆菌蛋白在制备诊断结核潜伏感染者和/或活动性肺结核产品中的用途
CA3118924A1 (en) 2018-11-09 2020-05-14 Ginkgo Bioworks, Inc. Biosynthesis of mogrosides
CN110129465B (zh) * 2019-05-22 2023-08-22 杭州优思达生物技术股份有限公司 一种海分枝杆菌核酸的快速检测方法及其试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
DE4221858A1 (de) 1992-07-03 1994-01-05 Becker Carl Chemie Gmbh Addukte von 0,0-Dialkyldithiophosphorsäuren an ungesättigte Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schmiermitteladditive
US6583266B1 (en) * 1993-08-19 2003-06-24 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to mycobacterium tuberculosis and leprae for diagnostics and therapeutics
US5783386A (en) 1994-02-24 1998-07-21 Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. Mycobacteria virulence factors and a novel method for their identification
SG119177A1 (en) 1994-12-09 2006-02-28 Imp College Innovations Ltd Identification of genes
US6572865B1 (en) * 1995-06-15 2003-06-03 University Of Victoria Innovation And Development Corporation Mycobacterium tuberculosis DNA sequences encoding immunostimulatory peptides and methods for using same
US5998194A (en) * 1995-12-21 1999-12-07 Abbott Laboratories Polyketide-associated sugar biosynthesis genes
CA2197524A1 (en) * 1996-02-22 1997-08-22 Bradley Stuart Dehoff Polyketide synthase genes
WO1997035611A1 (en) 1996-03-27 1997-10-02 The Johns-Hopkins University Stationary phase, stress response sigma factor from mycobacterium tuberculosis, and regulation thereof
CA2268036A1 (en) 1996-10-11 1998-04-23 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
GB9711389D0 (en) 1997-06-04 1997-07-30 Univ Wales The Bacterial pheromones and uses therefor
WO1999004005A1 (en) 1997-07-16 1999-01-28 Institut Pasteur A polynucleotide functionally coding for the lhp protein from mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same
WO1999010536A1 (en) 1997-08-22 1999-03-04 Yale University A process to study changes in gene expression in granulocytic cells
GB9723630D0 (en) 1997-11-07 1998-01-07 Stanford Rook Ltd M.vaccae preparation and its use
US6183957B1 (en) * 1998-04-16 2001-02-06 Institut Pasteur Method for isolating a polynucleotide of interest from the genome of a mycobacterium using a BAC-based DNA library application to the detection of mycobacteria
WO1999057130A1 (en) 1998-05-05 1999-11-11 Gene Logic, Inc. A process to study changes in gene expression in t lymphocytes
US6892139B2 (en) * 1999-01-29 2005-05-10 The Regents Of The University Of California Determining the functions and interactions of proteins by comparative analysis
GB9904773D0 (en) * 1999-03-02 1999-04-28 Microbiological Res Authority Culture of mycobacteria
US6573361B1 (en) * 1999-12-06 2003-06-03 Monsanto Technology Llc Antifungal proteins and methods for their use
US6613553B1 (en) * 2000-02-04 2003-09-02 St. Jude Children's Research Hospital Enoyl reductases and methods of use thereof
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
AU2002317940B9 (en) * 2001-06-22 2008-06-05 The Secretary Of State For Health Mycobacterial antigens expressed under low oxygen tension
US7393540B2 (en) * 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
GB0125535D0 (en) * 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency

Also Published As

Publication number Publication date
US20090082296A1 (en) 2009-03-26
US20120034689A1 (en) 2012-02-09
WO2003004520A3 (en) 2003-10-16
US20040241826A1 (en) 2004-12-02
JP2005508613A (ja) 2005-04-07
US8003776B2 (en) 2011-08-23
US7393540B2 (en) 2008-07-01
AU2008243118A1 (en) 2008-11-27
US8399650B2 (en) 2013-03-19
AU2002314358B2 (en) 2008-08-14
EP2196473A1 (en) 2010-06-16
AU2002314358C1 (en) 2009-03-26
EP1404706A2 (en) 2004-04-07
WO2003004520A2 (en) 2003-01-16
CA2453173A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
US8003776B2 (en) Mycobacterial antigens expressed during latency
US8017753B2 (en) Mycobacterial antigens expressed under low oxygen tension
AU2002314358A1 (en) Mycobacterial antigens expressed during latency
US20110091881A1 (en) Mycobacterial genes down-regulated during latency
US20030147897A1 (en) M. tuberculosis antigens
US6641814B1 (en) Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
AU2002317940A1 (en) Mycobacterial antigens expressed under low oxygen tension
TWI328035B (en) Anti-bacterial vaccine compositions
US20040115211A1 (en) TB diagnostic based on antigens from M. tuberculosis
AU2002336179A1 (en) Mycobacterial genes down-regulated during latency
US20040110269A1 (en) Protection against mycobacterial infections
WO2003033530A2 (en) Mycobacterial antigens expressed under high oxygen tension
JP2002504321A (ja) 新規ｐｇｓＡ

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150706